PT-141 Australia: Research Overview
A neutral, factual look at PT-141 (bremelanotide), the melanocortin receptor agonist peptide, including its mechanism, its regulatory position abroad and in Australia, and anti-doping context, framed strictly for laboratory research use. General information only, not legal or medical advice.
The short answer
PT-141, also known as bremelanotide, is a synthetic peptide studied in research settings as a melanocortin receptor agonist. Abroad, a bremelanotide product is approved by the United States FDA for one specific medical indication, but it is not registered by the Therapeutic Goods Administration (TGA) in Australia as a consumer medicine on the Australian Register of Therapeutic Goods (ARTG). NovaPeptides supplies PT-141 strictly for laboratory research use only, not for human use. This page is an educational overview and makes no claims about outcomes for any person.
General information only, not legal or medical advice. PT-141 is supplied for laboratory research use only and is not intended for human or veterinary use, consumption, or administration. Nothing here describes dosing, protocols, or how to prepare or use the peptide. For regulatory or health questions, consult the TGA and a qualified professional.
What PT-141 is
PT-141 is a laboratory name for bremelanotide, a synthetic cyclic heptapeptide. In the research literature it is described as an analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring signalling peptide in the melanocortin system. Because it is built on the alpha-MSH template, it is studied for how it interacts with the family of melanocortin receptors.
In structural terms, PT-141 is a small, cyclised peptide. The cyclic design is a common strategy in peptide chemistry intended to improve stability compared with simple linear sequences. As a research reagent it is typically supplied as a lyophilised (freeze-dried) powder and stored cold. The sequence and identity are what a certificate of analysis (COA) is designed to confirm.
At a glance
- Common research name: PT-141
- Compound: bremelanotide
- Class: synthetic cyclic heptapeptide
- Template: analogue of alpha-MSH
- Supplied by NovaPeptides: research use only, with a Novagen COA
Mechanism and receptor target
In published research, bremelanotide is characterised as a non-selective melanocortin receptor agonist. The melanocortin system includes several receptor subtypes, labelled MC1R through MC5R. Bremelanotide shows activity across more than one of these subtypes, with the melanocortin-4 receptor (MC4R) and melanocortin-3 receptor (MC3R) frequently highlighted in the literature, alongside activity at MC1R.
An agonist is a molecule that binds a receptor and activates it, in contrast to an antagonist that blocks it. Melanocortin receptors are found in various tissues and in regions of the central nervous system. Research on bremelanotide has focused on how activation of these receptors influences downstream signalling. This page describes that receptor interaction as a matter of pharmacology only and makes no claim about any effect in a person.
Bremelanotide is often distinguished in the literature from melanotan II, a related melanocortin-active peptide. They are different compounds with different regulatory and anti-doping positions, so they should not be treated as interchangeable.
The Vyleesi context abroad
As a factual regulatory matter about the United States, the FDA approved bremelanotide in June 2019. It is marketed there under the brand name Vyleesi for one specific indication in premenopausal women, namely a form of hypoactive sexual desire disorder. In research descriptions of the approved product, bremelanotide is administered by subcutaneous injection.
This is stated purely as a neutral fact about another country's regulator and about the published research context. It is not an efficacy claim, a recommendation, or a suggestion that the compound is suitable for any use by any reader. A regulatory approval in one country for one defined medical indication does not change the Australian position, and it says nothing about research-grade material sold here.
Australian regulatory status
In Australia, therapeutic goods for human use are expected to be entered on the Australian Register of Therapeutic Goods (ARTG) and are classified under the Poisons Standard. Bremelanotide is not registered by the TGA as a consumer medicine on the ARTG, so there is no TGA-approved bremelanotide product on the Australian market for general supply.
Peptides of this kind are generally treated as prescription-type substances under the Poisons Standard when intended for human therapeutic use, and a peptide that is not on the ARTG is regarded as an unapproved therapeutic good if it is marketed for human use. We do not assert a specific schedule number here. Researchers who need the exact current classification should check the Poisons Standard and the TGA directly, because scheduling can change over time.
NovaPeptides does not supply PT-141 for human use. It is offered as a research reagent for laboratory investigation only. That framing is deliberate: it reflects that the material is not a registered medicine and is not intended for consumption, administration, or any therapeutic purpose.
PT-141 from NovaPeptides is for in-vitro and laboratory research by qualified researchers. It is not for human or animal use. Buyers are responsible for complying with all applicable Australian laws and institutional requirements.
Anti-doping and WADA note
Anyone involved in sport should treat melanocortin-active peptides with care. The World Anti-Doping Agency (WADA) maintains a Prohibited List that is updated regularly and includes broad catch-all categories as well as named substances. Related melanocortin compounds have appeared in anti-doping discussions, so the status of a given peptide should never be assumed.
Because lists change and interpretations can be nuanced, researchers and athletes should check the current WADA Prohibited List, use tools such as Global DRO, and confirm with Sport Integrity Australia or the relevant national anti-doping organisation before drawing any conclusion. This page does not state a definitive anti-doping classification.
How NovaPeptides supplies PT-141
NovaPeptides lists PT-141 (bremelanotide) as a research-grade peptide for laboratory use only. Each batch is accompanied by a Novagen certificate of analysis (COA), which is the document used to confirm identity and purity for the lot supplied. A COA is central to research-grade material because it lets the researcher verify what they have received.
Orders ship within Australia. As with all NovaPeptides research compounds, the material is sold strictly for laboratory research and is not intended for human use, consumption, or administration. We provide no dosing guidance, no preparation instructions, and no protocols, consistent with research-use-only supply.
What ships with a research order
- Research-grade PT-141 (bremelanotide) as a lyophilised powder
- A Novagen certificate of analysis for the batch
- Australian shipping
- Clear research-use-only labelling
Frequently asked questions
Is PT-141 the same as bremelanotide?+
Yes. PT-141 is a commonly used research name for bremelanotide, a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist.
Is PT-141 approved by the TGA in Australia?+
No. Bremelanotide is not registered by the TGA as a consumer medicine on the ARTG, so there is no TGA-approved product for general supply. NovaPeptides supplies it for laboratory research use only.
Is PT-141 FDA approved?+
A bremelanotide product is approved by the United States FDA, marketed as Vyleesi, for one specific indication in premenopausal women. This is a neutral fact about US regulation and does not change the Australian position or imply any use for a reader.
What does PT-141 do at a receptor level?+
In research, bremelanotide is described as a non-selective melanocortin receptor agonist, with activity including MC4R, MC3R and MC1R. This describes pharmacology only, not any effect in a person.
Is PT-141 banned by WADA?+
The anti-doping position of melanocortin peptides should not be assumed. Check the current WADA Prohibited List, Global DRO, and Sport Integrity Australia before drawing any conclusion. This page does not state a definitive classification.
Can I use NovaPeptides PT-141 as a medicine?+
No. It is supplied strictly for laboratory research use only and is not intended for human or animal use, consumption, or administration. We provide no dosing or protocol information.
Does PT-141 come with a certificate of analysis?+
Yes. Each batch ships with a Novagen certificate of analysis used to confirm identity and purity for that lot, with Australian shipping.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp